WASHINGTON — The addition of evolocumab to statin therapy did not result in memory loss or other cognitive issues, according to results of the EBBINGHAUS study.
The investigators of FOURIER, which compared evolocumab (Repatha, Amgen) vs. placebo for clinical outcomes in patients with atherosclerotic CVD and elevated LDL on background statin therapy, undertook a cognitive substudy because small studies and case series had raised concerns that statins negatively impact cognitive outcomes, later disproven by larger studies, Robert P. Giugliano, MD, SM, cardiovascular medicine specialist at Brigham and Women’s Hospital and a senior investigator at the Thrombolysis in Myocardial Infarction Study Group, said during a presentation at the American College of Cardiology Scientific Session.
“We designed the EBBINGHAUS study ... to assess the following hypothesis: [Did] the addition of evolocumab to statin therapy in patients with clinically evident [CVD] affect cognitive outcomes? We hypothesized that it would not,” Giugliano said.
Robert P. Giugliano
To determine whether that was true, the researchers enrolled 1,974 patients from FOURIER (mean age, 63 years; 72% men) without dementia or cognitive impairment at baseline, of whom 1,204 who had baseline cognitive testing performed and at least one follow-up cognitive test were included in the primary analysis.
All patients performed Cambridge Neuropsychological Test Automated Battery Assessments at baseline, 6 months, 12 months, 24 months, 48 months and at the end of the study.